Table 1.
The primer for amplification of HRPT2/CDC73 gene.
Table 2.
Clinical characteristics and HRPT2/CDC73 mutations in patients of parathyroid carcinoma.
Table 3.
Clinical characteristics and HRPT2/CDC73 mutations in subjects of control groups.
Figure 1.
Mutations of HRPT2/CDC73 gene.
Table 4.
Mutations of HRPT2/CDC73 gene in patients with parathyroid carcinoma.
Table 5.
Comparison between the PC patients with and without HRPT2/CDC73 mutation.
Figure 2.
H&E staining and IHC staining in tissue samples of different types of PHPT(200×).
NP, normal parathyroid tissue; PH, parathyroid hyperplasia PA, parathyroid adenoma; PC, parathyroid carcinoma A–D H&E staining of normal parathyroid tissue,parathyroid hyperplasia, parathyroid adenoma and parathyroid carcinoma E–G IHC of Parafibromin is specific nuclear staining in normal parathyroid tissue,parathyroid hyperplasia, parathyroid adenoma, brown granulation can be seen in positive nuclear side H Typical loss staining of Parafibromin in PCA–D H&E staining of normal parathyroid tissue,parathyroid hyperplasia, parathyroid adenoma and parathyroid carcinoma E–G IHC of Parafibromin is specific nuclear staining in normal parathyroid tissue, parathyroid hyperplasia, parathyroid adenoma, brown granulation can be seen in positive nuclear side H Typical loss staining of Parafibromin in PC.